HomeCompareNURO vs MCD

NURO vs MCD: Dividend Comparison 2026

NURO yields 43.67% · MCD yields 2.34%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NURO wins by $204.8K in total portfolio value
10 years
NURO
NURO
● Live price
43.67%
Share price
$4.58
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$282.6K
Annual income
$51,335.69
Full NURO calculator →
MCD
McDonald's Corporation
● Live price
2.34%
Share price
$310.79
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$25,833.37
Full MCD calculator →

Portfolio growth — NURO vs MCD

📍 NURO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNUROMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NURO + MCD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NURO pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NURO
Annual income on $10K today (after 15% tax)
$3,711.79/yr
After 10yr DRIP, annual income (after tax)
$43,635.34/yr
MCD
Annual income on $10K today (after 15% tax)
$198.56/yr
After 10yr DRIP, annual income (after tax)
$21,958.36/yr
At 15% tax rate, NURO beats the other by $21,676.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NURO + MCD for your $10,000?

NURO: 50%MCD: 50%
100% MCD50/50100% NURO
Portfolio after 10yr
$180.2K
Annual income
$38,584.53/yr
Blended yield
21.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

NURO
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-14.9
Piotroski
1/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+13.2% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NURO buys
0
MCD buys
0
No recent congressional trades found for NURO or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNUROMCD
Forward yield43.67%2.34%
Annual dividend / share$2.00$7.26
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3%
Portfolio after 10y$282.6K$77.7K
Annual income after 10y$51,335.69$25,833.37
Total dividends collected$217.9K$57.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: NURO vs MCD ($10,000, DRIP)

YearNURO PortfolioNURO Income/yrMCD PortfolioMCD Income/yrGap
1← crossover$15,067$4,366.81$10,812$332.41+$4.3KNURO
2$22,270$6,148.97$11,819$488.02+$10.5KNURO
3$32,324$8,494.27$13,111$724.37+$19.2KNURO
4$46,108$11,522.15$14,832$1,091.05+$31.3KNURO
5$64,697$15,360.67$17,219$1,675.85+$47.5KNURO
6$89,369$20,143.18$20,688$2,641.85+$68.7KNURO
7$121,629$26,004.42$25,990$4,309.70+$95.6KNURO
8$163,219$33,076.14$34,590$7,351.77+$128.6KNURO
9$216,127$41,482.53$49,535$13,285.25+$166.6KNURO
10$282,592$51,335.69$77,746$25,833.37+$204.8KNURO

NURO vs MCD: Complete Analysis 2026

NUROStock

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Full NURO Calculator →

MCDConsumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this NURO vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NURO vs SCHDNURO vs JEPINURO vs ONURO vs KONURO vs MAINNURO vs YUMNURO vs QSRNURO vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.